SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are strongly recommended for patients with type 2 diabetes in the latest clinical practice guidelines based on their demonstrated cardiovascular and renal benefits1.